 The present study updates a previous evaluation of the cost-effectiveness of the herpes zoster, HZ, vaccine from a Swiss third-party pair perspective, using updated vaccine prices, a different age cohort, latest clinical data and burden of illness data. The results show that vaccination of 15% of the Swiss population aged 65-79 backslash ZA0Y would result in an additional cost of 17,720,087 Swiss francs and gain 594 quality adjusted life years, QALYs, with an incremental cost-effectiveness ratio, ICER, of 29,814 Swiss francs per QALY gained. Sensitivity analyses showed that the results were most sensitive to epidemiological inputs, utility values, discount rates, duration of vaccine efficacy, and vaccine price. Probabilistic sensitivity analyses indicated a more than 99% chance that the ICER was below 40,000 Swiss francs per QALY. The updated study supports the value of an HZ vaccination strategy targeting the Swiss population aged 65-79 backslash ZA0Y.